Isomaltulose and Isomalt Biocatalytic Production
Advanced biomanufacturing and industrial formulation of isomaltulose and isomalt biocatalytic production. Dissolving food-grade refined sucrose into 40-50% Brix aqueous syrup under pasteurization conditions..
1 · What it gives
Isomaltulose and Isomalt Biocatalytic Production represents a critical node in high-value fine chemical and active pharmaceutical ingredient (API) biomanufacturing, overcoming the thermodynamic limits, toxic waste streams, and low stereoselectivity associated with legacy multi-step organometallic synthesis. Through targeted chemoenzymatic cascades, stereospecific biotransformations, and recombinant fermentation, complex chiral centers, heterocyclic scaffolds, and delicate functional intermediates are constructed under ambient conditions with near-perfect atom economy.
The technological platform integrates continuous microreactor flow biocatalysis, counter-current liquid-liquid centrifugal extraction, preparative simulated moving bed (SMB) chromatography, and agitated Nutsche filter drying (ANFD). Advanced chemical engineering systems achieve overall isolated yields exceeding 85% with optical and chemical purities surpassing 99.8%. Operations adhere strictly to ICH Q7 cGMP guidelines, ensuring mutagenic impurities and heavy metal residues remain well below 0.05% thresholds in full compliance with global pharmacopeias.
The key directions of this technology are:
- Chemoenzymatic Route Engineering in Isomaltulose and Isomalt Biocatalytic Production: Interlocking synthetic organic chemistry with stereospecific biocatalytic steps (ketoreductases, transaminases) to truncate synthetic routes by up to 60%.
- Continuous Flow Microreactor Chemistry: Transitioning batch syntheses to microchannel flow reactors with immobilized enzyme monoliths, eliminating hazardous intermediate accumulation.
- Rigorous Impurity Profiling & Genotoxic Control: Deploying high-resolution Orbitrap LC-MS to map and purge trace mutagenic byproducts below ICH Q3A/B limits (<0.05%).
- Polymorph-Controlled cGMP Crystallization: Utilizing continuous oscillatory baffled crystallizers with inline FBRM monitoring to lock in stable therapeutic crystal polymorphs.
Sectoral value chain#
┌────────────────────────────────────────────────────────┐
│ Tier 1: Chiral Precursor Activation & Sourcing │
│ (Starting materials cGMP assay & pre-activation) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 2: Chemoenzymatic Continuous Flow Reactor │
│ (Immobilized enzyme microchannel with cofactor recycle│
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 3: Counter-Current Centrifugal Extraction │
│ (Multi-stage liquid-liquid organic solvent partition) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 4: Preparative Chiral SMB Chromatography │
│ (Simulated moving bed resolving optical antipodes) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 5: ANFD Controlled Crystallization & Drying │
│ (Enclosed Nutsche filter drying & jet micronization) │
└────────────────────────────────────────────────────────┘
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| Starting Material Activation | Synthesis, incoming compendial quality control, and dissolution of pro-chiral key starting materials (KSM). | In: Commercial fine chemicals, solvents, activation reagents. Out: Sterile, analytical-grade pro-chiral feed solution (>98.5% purity). |
| Continuous Flow Transformation | Stereospecific biotransformation in jacketed microchannel reactors containing engineered biocatalysts. | In: Pro-chiral substrate, immobilized enzymes, recycled NADPH. Out: High-conversion reaction stream (>99.0% conversion, ee >99.8%). |
| Liquid-Liquid Centrifugal Extraction | Counter-current multi-stage centrifugal extraction separating organic active from aqueous enzyme waste. | In: Reaction effluent, pharmaceutical ethyl acetate/heptane. Out: Concentrated organic product extract (spent enzymes separated). |
| Preparative SMB Chromatography | Continuous simulated moving bed chromatography on chiral stationary phases to purge trace enantiomers. | In: Organic extract, mobile phase solvents. Out: Chromatographically pure API stream (all impurities <0.10%). |
| Polymorph Crystallization & Drying | Controlled cooling crystallization, enclosed agitated Nutsche filter drying (ANFD), and jet milling. | In: Purified stream, seed crystals, pharmaceutical nitrogen. Out: Compendial-grade micronized cGMP API (>99.8% purity, Form I). |
Cross-cutting technologies of the sector:
- Enclosed Agitated Nutsche Filter Dryers (ANFD): Contained pressure filtration, multi-solvent displacement washing, and vacuum drying in a single cGMP vessel.
- Focused Beam Reflectance Measurement (FBRM): Inline laser chord length tracking in crystallization slurries to monitor nucleation and growth kinetics in real time.
2 · What it replaces 6 · matched by industry
| D3E– | Enzymatic high-fructose syrup from starch instead of sucrose and acid hydrolysis Replaces: Cane and beet sucrose in beverages and processed foods; acid hydrolysis of starch for glucose syrup | FOOD |
| D2E– | Enzymatic degumming (phospholipases) and enzymatic interesterification (immobilized lipases) of edible oils instead of acid–caustic chemical degumming and sodium-methoxide chemical interesterification Replaces: Phosphoric/citric acid plus caustic soda degumming and neutralization (soapstock, wastewater, oil losses); chemical interesterification with … | FOOD |
| D3E– | Citric acid by Aspergillus niger fermentation instead of extraction from citrus fruit Replaces: Citric acid extracted from lemons, limes and other citrus (calcium citrate route, Italy and California before 1930) | FOOD |
| D1E– | Baking enzymes (fungal amylase, maltogenic amylase, xylanase, glucose oxidase, lipase) plus ascorbic acid instead of potassium bromate and azodicarbonamide as flour treatment agents Replaces: Potassium bromate (KBrO₃) and azodicarbonamide (ADA) used as oxidizing flour improvers/dough conditioners; part of chemical emulsifier use … | FOOD |
| D1E– | Fermentation and algal food colours instead of azo dyes (tartrazine, sunset yellow) and titanium dioxide Replaces: Azo food dyes — tartrazine (E102), sunset yellow (E110), azorubine (E122), ponceau 4R (E124), allura red (E129); titanium dioxide (E171) … | FOOD |
| D1E3 | Fermentation and plant-derived sweeteners instead of aspartame, saccharin and sucralose Replaces: Artificial high-intensity sweeteners — aspartame (IARC 2B since 2023), saccharin, sucralose, acesulfame-K in beverages and dairy; part of … | FOOD |
3 · How to implement 4 steps
- 1Sucrose Feedstock DissolutionFeedstock & raw materials
- 2Immobilized Sucrose Isomerase TransformationStrains & cell lines
- 3Cooling Crystallization of PalatinosePurification & downstream
- 4Catalytic Hydrogenation to Isomalt
4 · Who delivers
Matched suppliers (matched automatically)
| Aminoverse BV | Netherlands | Equipment | active |
| Enzymaster 酶赛生物 | China | Producer | active |
| eversyn GmbH | Germany | Producer | active |
| Isomerase | United Kingdom | Producer | active |
| Sappi (JSE: SAP) | South Africa | Producer | active |
| Alchemy Foodtech | Singapore | Producer | active |
| Formulaciones Químicas, S.A. | Costa Rica | Producer | active |
| Aum Enzymes / Infinita Biotech | India | Producer | active |
| Zar Grain Refinery (Zar Fructose) | Iran | Producer | active |
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Novonesis (Novozymes) | 🇩🇰 Denmark | Industrial Enzyme Platforms & Microbial Solutions | Standardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation. | Commercial Scale |
| Codexis | 🇺🇸 United States | CodeEvolver Directed Evolution & API Biocatalysts | Standardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation. | Commercial Scale |
| BASF | 🇩🇪 Germany | Integrated Chemical & Biocatalytic Synthesis | Standardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation. | Commercial Scale |
| Enzymaster | 🇨🇳 China | Engineered Biocatalysts & Chiral Fine Chemicals | Standardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation. | Commercial Scale |
| Lonza | 🇨🇭 Switzerland | Microbial CDMO & Custom Biocatalysis Platforms | Standardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation. | Commercial Scale |
| Evonik Industries | 🇩🇪 Germany | Fermentation Biosurfactants & Specialty Intermediates | Standardized cGMP / ISO 9001 biocatalytic validation and high-titer downstream isolation. | Commercial Scale |
5 · Rules & route to market
declaration of conformity, or SGR within 30 calendar days for new/specialized ingredients (plus tests)
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States
FDA CDER cGMP compliance, Type II Drug Master File (DMF), BARDA critical onshoring#
- FDA 21 CFR Part 210/211 cGMP Compliance: Comprehensive operational validation and quality assurance for active pharmaceutical manufacturing of Isomaltulose and Isomalt Biocatalytic Production.
- Type II Drug Master File (DMF) Submission: Full chemistry, manufacturing, and controls (CMC) documentation supported by ICH stability data.
- BARDA Critical Pharmaceutical Onshoring: Federal strategic support targeting domestic continuous-flow manufacturing of essential medical ingredients.
European Union
EMA Active Substance Master File (ASMF), EDQM CEP certification, Critical Medicines Alliance#
- EMA & EDQM CEP Certification: Issuance of Certificates of Suitability demonstrating adherence to European Pharmacopoeia (Ph. Eur.) standards.
- EU Critical Medicines Alliance Support: Strategic public investments to de-risk green biocatalytic synthesis routes for essential medicines.
- ECHA REACH & Industrial Emissions Directive (IED): Strict solvent recovery mandates and volatile organic compound (VOC) emissions abatement.
China
14th Five-Year Bioeconomy Strategy, National Medical Products Administration (NMPA) GMP, ChP 2025#
- Green Pharmaceutical Manufacturing Priority: Strategic industrialization of 异麦芽酮糖与异麦芽酮糖醇生物催化制造技术 within API hubs across Zhejiang, Jiangsu, and Shandong.
- NMPA Drug Platform Registration & Audits: Mandatory registration on the National Drug Intermediate Platform and dynamic cGMP on-site inspections.
- Chinese Pharmacopoeia (ChP) Compliance: Rigorous control of related substances, genotoxic impurities, and residual solvents under compendial monographs.
6 · Money: tenders & grants
| Grant | Circular innovative advanced materials: facilitating the transition from design to markets (RIA) (Innovative … European Commission · EU | Feb 2, 2027 71 days |
| Grant | Development of cell-free protein synthesis platforms for discovery and/or production of biologicals European Commission · EU | Apr 13, 2027 141 days |
| Grant | Fostering common farmland birds and mammals for resilient food production systems European Commission · EU | Sep 22, 2027 303 days |
| Grant | Unleashing the potential of sustainable small-scale aquatic food production and recreational fisheries for … European Commission · EU | Sep 23, 2027 304 days |
| Grant | Textile circularity through advanced processing and manufacturing technologies and system approaches (IA) … European Commission · EU | Feb 2, 2027 71 days |
7 · Tech stack & innovations
- Chemoenzymatic Cascade Design in Isomaltulose and Isomalt Biocatalytic Production:
- Coupled ketoreductase and transaminase cascades installing complex chiral centers with absolute stereochemical control (ee >99.8%).
- Computational retrosynthetic route truncation reducing total synthetic step count from 8 chemical stages to 3 biocatalytic operations.
- Microreactor Flow Chemistry & Extraction:
- Hastelloy continuous flow microchannels providing exceptional heat transfer rates (>10,000 W/m²·K) for exothermic biotransformations.
- Multi-stage counter-current centrifugal liquid-liquid extractors achieving complete product recovery with low solvent consumption.
- Continuous SMB Chromatography & Crystallization:
- Industrial simulated moving bed (SMB) chiral column trains resolving optical antipodes with solvent recovery exceeding 95%.
- Automated continuous oscillatory baffled crystallizers (COBC) utilizing inline FBRM probes to enforce metastable zone width control.
Sources 2 · 2 independent · 0 producer sites
Independent sources 2
- www.ncbi.nlm.nih.gov research checked 2026-11-15
- doi.org research checked 2026-11-15